A digital health company had built a promising product.
The software could analyze patient data, connect with devices such as blood pressure monitors, and help clinicians make faster decisions. The technology worked. The team was preparing for launch.
Then someone asked:
“Is this software considered a medical device?”
That question changed everything.
Once software is used for a medical purpose, it may fall under Software as a Medical Device (SaMD) requirements. The conversation quickly moves beyond features and performance. The team now has to think about regulatory classification, quality systems, software validation, clinical evidence, cybersecurity, risk management, and market approval. This is where many companies discover that building the product is only half the journey.
Where SaMD projects usually get complicated
A software team may already be working in agile sprints, releasing updates quickly, and improving the product based on user feedback.
That works well for traditional software. For SaMD, every important product decision may also have a regulatory impact. Changing an algorithm, adding a new clinical claim, integrating with a blood pressure monitor, or changing how a risk score is displayed can affect documentation, testing, risk analysis, and in some cases the regulatory pathway itself. The challenge is not simply creating more documents. It is keeping the product, evidence, software development process, and regulatory strategy aligned.
Connected devices add another layer.
Many SaMD products receive data from blood pressure monitors, glucose meters, pulse oximeters, ECG devices, wearables, remote patient monitoring systems, hospital systems, or mobile applications.
A blood pressure monitor, for example, may collect the measurement, while the software analyzes trends, flags abnormal readings, or supports a clinical decision.
That software function may carry a very different regulatory significance from an app that simply stores readings.
This is why intended use matters so much.
The biggest mistake is often starting too late
A common situation looks like this:
The product is nearly finished. The software works. The company is ready to enter the market. Then the regulatory review begins. At that point, the team may find that software requirements are incomplete, risk controls were never formally documented, testing is not fully traceable, cybersecurity records are missing, or clinical claims are not supported by enough evidence.
Now the team has to go back and rebuild parts of the development history. That creates delay and cost .A better approach is to bring regulatory thinking into development early enough that compliance becomes part of the workflow rather than a cleanup exercise before submission.
Clinical evidence matters as much as technical performance
A technically accurate product is not automatically a clinically meaningful product.
If software analyzes blood pressure readings and predicts cardiovascular risk, regulators and customers may want to know more than whether the code runs correctly. They may ask whether the algorithm has a valid clinical basis, whether it was tested on the right population, how accurate the output is, what happens if the software gives the wrong result, and whether the claims are supported by evidence. These questions are much easier to address when they are considered early.
Cybersecurity is part of product safety
SaMD products often connect to cloud systems, APIs, mobile devices, hospital networks, and third-party software. That means cybersecurity is not just an IT concern.
A vulnerability could affect data integrity, product availability, or clinical decision-making. Cybersecurity should therefore be considered throughout development, including access control, software components, vulnerability management, secure updates, threat analysis, and post-market monitoring.
Where SaMD consulting adds value
Most companies do not need someone to simply tell them that regulations exist.
They need someone who can translate those requirements into practical work.
That means answering questions such as:
- Is our software regulated as a medical device?
- What is the likely classification?
- What regulatory pathway applies?
- Are our current development processes suitable?
- What documentation is missing?
- What evidence do we need?
- Are our clinical claims supportable?
- How should future software updates be managed?
This is where SaMD consulting becomes useful. A good consultant helps the team understand what is required, what already exists, where the gaps are, and what should happen next.
A practical way to start
For many companies, the best first step is a SaMD Regulatory and Readiness Assessment. This can review the product, intended use, software architecture, development process, clinical evidence, risk management, cybersecurity, and target markets.
The goal is not to produce a long report that sits on a shelf. It is to give the team a practical roadmap showing where the product stands today, what the likely regulatory pathway is, what gaps need to be closed, and what should be prioritized before submission or launch.
From there, support can expand into regulatory strategy, QMS implementation, software lifecycle documentation, validation, risk management, clinical evidence planning, cybersecurity readiness, AI/ML regulatory support, and submission preparation.
SaMD should not be an afterthought
The strongest SaMD companies do not separate product development from regulatory strategy. They build both together. Whether the product connects to a blood pressure monitor, analyzes ECG data, supports remote patient monitoring, or uses AI to assist clinical decisions, the principle is the same:
Build the regulatory path alongside the product, not after it.
Need help with your SaMD program?
If you are developing medical software, preparing for regulatory submission, or trying to understand whether your product is ready for market, we can help you identify the gaps and define a clear path forward.
Contact us to discuss your SaMD product, regulatory strategy, or readiness assessment.
